Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.52
$0.01(0.66%)
At close: 4:00 PM EDT
$1.52
$0.01(0.66%)
Day’s Range― - ―
52-Week Range$1.15 - $2.54
Previous Close$1.56
Volume216.20K
Average Volume (3M)735.57K
Market Cap
$71.50M
Enterprise Value$84.28
Total Cash (Recent Filing)$205.03M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Nov 13, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding46,125,824
10 Day Avg. Volume409,704
30 Day Avg. Volume735,574
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.67Price Target Upside470.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.73
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
Debt-Free Recent Balance SheetThe absence of reported debt reduces near-term refinancing pressure and interest obligations, giving the company more flexibility to direct available capital toward clinical development while it remains pre-commercial.
Expanded Clinical Funding AccessThe new equity facility broadens access to capital and allows funding to be raised progressively for trials and research. That flexibility can support pipeline execution, although future issuance may dilute shareholders.
Oncology Leadership And Development MilestonesAdding an oncology executive with experience at Guardant Health, Genentech and Pfizer may strengthen development and regulatory execution. The stated Phase 3 and approval objectives provide a longer-term path toward commercialization.
Bears Say
No Commercial Revenue And Deepening LossesAbsent commercial revenue and consistently negative gross profit show that the business has not yet validated a revenue model. Expanding losses increase the capital required to reach clinical and regulatory milestones.
Persistent Cash BurnOngoing operating and free-cash-flow deficits mean the company cannot currently fund its activities internally. Continued dependence on financing leaves development plans exposed to funding availability and execution risk.
Dilutive And Secured Financing StructureSecured convertible financing provides liquidity but can dilute existing holders through conversions and warrants. Liens and covenants also constrain financial flexibility, increasing the consequences of weaker-than-planned clinical progress.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.54 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $71.50M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Nov 13, 2026 which is in 79 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Aug 17, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.022.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.15.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 46,125,824 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -9.259%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (470.18% Upside)
$8.67 (470.18% Upside)
Blogger Sentiment
Bullish
OSTX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.01%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$8.67
▲(470.18% Upside)
Technical Analysis
Ownership Overview
8.02% Insiders
1.49% Mutual Funds
1.68% Other Institutional Investors
86.79% Public Companies and
Individual Investors